Actelion (Actelion) Interest Expense : $-0 Mil (TTM As of Mar. 2017)

View and export this data going back to . Start your Free Trial

What is Actelion Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Actelion's interest expense for the three months ended in Mar. 2017 was $ 0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2017 was $-0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Actelion's Operating Income for the three months ended in Mar. 2017 was $ 214 Mil. Actelion's Interest Expense for the three months ended in Mar. 2017 was $ 0 Mil. Actelion has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Actelion Interest Expense Historical Data

The historical data trend for Actelion's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Interest Expense Chart

Actelion Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Interest Expense

Get a 7-Day Free Trial

-45.13

-43.92

-10.06

-20.26

Actelion Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Interest Expense	Get a 7-Day Free Trial															-1.23	-	-	-0.11	-

Actelion Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0 Mil.

Actelion (OTCPK:ALIOF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Actelion's Interest Expense for the three months ended in Mar. 2017 was $0 Mil. Its Operating Income for the three months ended in Mar. 2017 was $214 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2017 was $0 Mil.

Actelion's Interest Coverage for the quarter that ended in Mar. 2017 is calculated as

Actelion had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Actelion (Actelion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.actelion.com

Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 02-14-2017

Jean Hynes Reduces Stake in Actelion

By Kyle Ferguson Kyle Ferguson • 08-03-2016

Actelion Still On Growth Track

By reports.droy reports.droy • 02-18-2015

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 01-24-2017